IPP Bureau
Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr
By IPP Bureau - October 28, 2024
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr
By IPP Bureau - October 28, 2024
Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024
Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr
By IPP Bureau - October 28, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
AIIMS Delhi hosts workshop on ‘Emerging Technologies for Healthcare’
By IPP Bureau - October 28, 2024
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr
By IPP Bureau - October 26, 2024
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Glenmark Life Sciences posts Q2 FY25 net profit at Rs. 95.31 Cr
By IPP Bureau - October 26, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Mankind Pharma completes acquisition of BSV
By IPP Bureau - October 25, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr
By IPP Bureau - October 25, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr
By IPP Bureau - October 25, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr
By IPP Bureau - October 25, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr
By IPP Bureau - October 25, 2024
Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
By IPP Bureau - October 25, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs
By IPP Bureau - October 23, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Jubilant Ingrevia appoints Vijay Srivastava as Chief of Operations
By IPP Bureau - October 23, 2024
He has more than 25 years of experience in manufacturing across various industries including petrochemicals, engineering polymers, agrochemicals, organic, and inorganic intermediates
Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr
By IPP Bureau - October 23, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
